Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer This study will evaluate the efficacy and toxicity of docetaxel, gemcitabine and bevacizumab combination, administered biweekly, as salvage treatment in patients with metastatic and HER2 n...

• Pays Greece
• Organes Aucun
• Spécialités Aucune

Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer The combination of docetaxel+epirubicin is highly effective and well tolerated as first line treatment in patients with metastatic breast cancer (MBC). Capecitabine is an active drug in wo...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer Anthracycline-containing regimens are recommended as adjuvant treatment for women with node positive breast cancer. In at least three large randomized clinical trials the addition or seque...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer DOXORUBICIN is recognized as one of the most active drugs for breast cancer, but its clinical utility is limited because of a cumulative dose-dependent cardiac myopathy that can lead to po...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Myocet Plus Endoxan for Older Patients With Breast Cancer This study will evaluate the efficacy, safety and effect on quality of life of liposomal-encapsulated doxorubicin in combination with cyclophosphamide as first or second line treatment of ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer In this trial investigators propose to assess the dose dense, G-CSF supported sequential administration of 4 cycles of FEC followed by 4 cycles of docetaxel versus 6 cycles of docetaxel/cy...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients The optimal treatment for pretreated patients with metastatic breast cancer has not been established. Gemcitabine and capecitabine are two active agents in this setting. For women with Her...

• Pays Greece
• Organes Aucun
• Spécialités Aucune

Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer The purpose of this study is to evaluate the safety and efficacy of metronomic oral vinorelbine taken three times a week plus daily lapatinib without break, as salvage treatment in patient...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer This study will evaluate the efficacy, safety and effect on quality of life of weekly paclitaxel plus bevacizumab as first line treatment in elderly patients (≥ 70 years old) with metastat...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer This study will evaluate the efficacy of weekly paclitaxel-carboplatin combination plus bevacizumab as first line treatment in patients with metastatic triple negative breast cancer. Furth...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune